RxDoctor Payments DataLook up a doctor →

Christina Hatcher

Family · Kansas City, MONPI 1184387524

Payments from drug & device makers

$11,999in general payments, 2019–2025

Across 681 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2K
  • AbbVie$1K
  • UCB, Inc.$831
  • Bristol Myers Squibb$746
  • Novartis$668
  • Acadia Pharmaceuticals Inc$656
  • plus $6K from 47 others

What the payments were for

  • Food & beverage$11,93699%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,999 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$27,182
Medicare patients
96
Services billed
2,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab51$537,853
Nurtec OdtRimegepant Sulfate79$149,321
UbrelvyUbrogepant88$133,956
VumerityDiroximel Fumarate14$119,040
QuliptaAtogepant79$104,155
CopaxoneGlatiramer Acetate15$86,076
Avonex Pen (4 Pack)Interferon Beta-1a11$80,741
Aimovig AutoinjectorErenumab-Aooe49$38,947
Emgality PenGalcanezumab-Gnlm28$20,177
Dalfampridine ErDalfampridine35$6,641
Lidocaine28$2,652
Gabapentin103$2,504
Dimethyl Fumarate16$2,327
Baclofen23$1,108
Memantine Hcl34$847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,274$238,111167 claims
PfizerNurtec Odt$439$149,32179 claims
BiogenVumerity$1,740$119,04014 claims
Teva Pharmaceuticals USA, Inc.Copaxone$365$86,07615 claims
Upsher-smith Laboratories LLCTopiramate$21$21325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →